Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDER PAN study of dabigatran etexilate and rivaroxaban pharmacokinetics in short bowel syndrome with home TPN
NL-OMON38688Phase 1Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rivaroxaban and dabigatran in catheter-related thrombosis (CRT) and venous thromboembolism (VTE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary PK/PD assessment. Started Oct 2013; status: active, not recruiting.
02
Drugs
rivaroxabandabigatran
03
Conditions
catheter-related thrombosis (CRT)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON38688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38688.